{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:58:40Z","timestamp":1791460720878,"version":"4.3.4"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhep.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:50:12Z","timestamp":1787295012000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: \u201cRifaximin and the DCA\u2013serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?\u201d"],"prefix":"10.1016","author":[{"given":"Ke-Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7137-112X","authenticated-orcid":false,"given":"Wei-Fen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.08.015_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2026.06.018","article-title":"Rifaximin and the DCA-serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?","author":"Kalal","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.015_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.015_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2026.05.001","article-title":"Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acid","volume":"85","author":"Xiong","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.015_bib4","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2025.06.020","article-title":"Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community","volume":"83","author":"Hansen","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.015_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1053\/j.gastro.2024.06.007","article-title":"Targeting 5-Hydroxytryptamine Receptor 1A in the portal vein to decrease portal hypertension","volume":"167","author":"Zhu","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826028588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826028588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:33:32Z","timestamp":1791459212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826028588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":5,"alternative-id":["S0168827826028588"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.015","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: \u201cRifaximin and the DCA\u2013serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.05.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}